KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells

BACKGROUND: We previously described a sub-population of epithelial ovarian cancer (EOC) cells with a functional TLR-4/MyD88/NF-κB pathway (Type I EOC cells), which confers the capacity to respond to Paclitaxel, a known TLR-4 ligand, by enhancing NF-κB activity and upregulating cytokine secretion – e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ki Hyung, Xie, Yanhua, Tytler, Ewan M, Woessner, Richard, Mor, Gil, Alvero, Ayesha B
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719595/
https://www.ncbi.nlm.nih.gov/pubmed/19619321
http://dx.doi.org/10.1186/1479-5876-7-63

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719595/
https://www.ncbi.nlm.nih.gov/pubmed/19619321
http://dx.doi.org/10.1186/1479-5876-7-63

Ejemplares similares